Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor

Condition:   Neuroendocrine CarcinomaInterventions:   Biological: Recombinant Interferon Alfa-2b;   Drug: Octreotide Acetate;   Biological: BevacizumabSponsor:   National Cancer Institute (NCI)Active, not recruiting - verified September 2014
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials